Side-Effects of Anti-Inflammatory Drugs 3

Side-Effects of Anti-Inflammatory Drugs 3 edited by K. D. Rainsford, G.P Velo.

The contents of this book represent papers which were presented at the Third International Meeting on "Side-Effects of Anti-Inflammatory and Analgesic Drugs" which was held under the auspices of the University of Verona, Institute of Pharmacology in Verona on 8-11 May 1991. This meeting wa...

Full description

Saved in:
Bibliographic Details
Corporate Author: SpringerLink (Online service)
Other Authors: Rainsford, K. D. (Editor), Velo, G.P (Editor)
Format: eBook
Language:English
Published: Dordrecht : Springer Netherlands : Imprint: Springer, 1992.
Edition:1st ed. 1992.
Series:Inflammation and Drug Therapy Series, 5
Springer eBook Collection.
Subjects:
Pharmacology.
Rheumatology.
Gastroenterology .
Hepatology.
Nephrology.
Electronic resources (E-books)
Online Access:Click to view e-book
Holy Cross Note:Loaded electronically.
Electronic access restricted to members of the Holy Cross Community.
Table of Contents:
  • Section I: Epidemiology
  • 1 The gastrointestinal toxicity of the non-steroidal anti-inflammatory drugs
  • 2 The value of the case-control approach for the evaluation of the risk of upper gastrointestinal bleeding associated with the previous use of non-steroidal anti-inflammatory drugs
  • 3 Liver toxicity of antipyretic drugs in conjunction with measles infections
  • 4 Non-steroidal anti-inflammatory drugs and hypersensitivity reactions
  • 5 What can a spontaneous reporting system teach about side-effects of anti-inflammatory drugs?
  • 6 Adverse reactions to NSAIDs: consecutive evaluation of 30 000 patients in rheumatology
  • Section II: Gastrointestinal Tract: Clinical Aspects
  • 7 The evaluation of acute gastrointestinal toxicity of NSAIDs in phase I clinical trials: a critical appraisal
  • 8 The ulcerogenic and anti-haemostatic effects of NSAIDs in the gut
  • 9 What role does Helicobacter pylori infection play in NSAID-associated gastric inflammation?
  • 10 Endoscopic evaluation of NSAID ulceration
  • 11 Food antigen absorption in rheumatoid arthritis: effect of acetylsalicylic acid
  • 12 Intestinal mucosal permeability in inflammatory rheumatic diseases
  • 13 Comparison of effects on gastrointestinal blood loss and gastric mucosal appearance of piroxicam-?-cyclodextrin, piroxicam and placebo
  • Section III: Gastrointestinal Tract: Prevention Of Adverse Effects
  • 14 Mechanisms of gastrointestinal ulceration from non-steroidal anti-inflammatory drugs: a basis for use and development of protective agents
  • 15 Novel strategies of gastric and duodenal mucosal protection against NSAID injury: role of protease inhibitors, muscle relaxants and growth factors
  • 16 The role of misoprostol in preventing NSAID-induced damage to the gastrointestinal tract
  • 17 Possible factors involved in the protective effects of interleukin-1 in aspirin- and indomethacin-induced gastric damage
  • 18 Prevention and treatment of NSAID-gastroduodenal damage: the role of H2-receptor antagonists
  • 19 Omeprazole in the prevention and therapy of gastroduodenal lesions on NSAID therapy
  • 20 Sucralfate in the prevention of NSAID-induced gastric ulceration
  • 21 Ketotifen - a novel approach to the prevention of damage in the gastrointestinal tract
  • Section IV: Hepatotoxicity
  • 22 The hepatotoxicity of non-steroidal anti-inflammatory drugs
  • 23 Paracetamol (acetaminophen) bioactivation by liver microsomes - its role in hepatotoxicity
  • 24 Increased liver toxicity of diclofenac by paracetamol: results and possible mechanisms
  • 25 Effects of NSAIDs on liver microsomal mono-oxygenase system and products of oxidative metabolism of arachidonic acid
  • 26 Hepatitis due to non-steroidal anti-inflammatory drugs (NSAIDs)
  • Section V: Nephrotoxicity
  • 27 Current status of nephrotoxicity caused by non-steroidal anti-inflammatory drugs
  • 28 Are oral prostaglandins effective in preventing nephrotoxicity from NSAIDs and cyclosporin?
  • Section VI: Specific Issues Related To Side-Effects
  • 29 Aspirin and Reye’s syndrome
  • 30 Antirheumatic drug therapy in the elderly
  • 31 NSAIDs and human cartilage metabolism
  • 32 Non-steroidal anti-inflammatory drugs and the augmented lipoxygenase pathway: conceivable impact on joint conditions
  • 33 Therapeutic potential of 5-lipoxygenase inhibitors: the discovery and development of MK-886, a novelmechanism leukotriene inhibitor
  • 34 Mechanisms of rash formation and related skin conditions induced by non-steroidal anti-inflammatory drugs
  • Section VII: Antirheumatic And Immunoregulatory Agents
  • 35 Cyclosporin: clinical efficacy and toxicity in patients with rheumatoid arthritis
  • 36 Risk factors and risk-benefit problems in the use of DMARDs
  • 37 Gold toxicity: chemical, structural, biological and clinical experimental issues
  • Section VIII: Extended Poster Presentations
  • 38 A review of interaction studies between non-steroidal anti-inflammatory drugs and HTreceptor antagonists or prostaglandin analogues
  • 39 Influence of different anti-inflammatory substances on ethanol- and indomethacin-induced gastrointestinal mucosal damage
  • 40 The role of copper in preventing gastric damage by acetylsalicylic acid
  • 41 Effect of NSAID therapy on plasma, whole blood cell (BC), and 24h urine zinc in patients with rheumatoid arthritis (RA).

Similar Items